Syn3, a newly developed cyclic peptide and BDNF signaling enhancer, ameliorates retinal ganglion cell degeneration in diabetic retinopathy

Ke-ran Li, Meng-Jia Huan, Jin Yao, Jia-jun Li, Yuan Cao, Suyu Wang, Mandar T. Naik, Yuan Fang, John Marshall, Chang-gong Lan, Cong Cao

PDF(35060 KB)
PDF(35060 KB)
Protein Cell ›› 2024, Vol. 15 ›› Issue (11) : 858-865. DOI: 10.1093/procel/pwae028
LETTER

Syn3, a newly developed cyclic peptide and BDNF signaling enhancer, ameliorates retinal ganglion cell degeneration in diabetic retinopathy

Author information +
History +

Cite this article

Download citation ▾
Ke-ran Li, Meng-Jia Huan, Jin Yao, Jia-jun Li, Yuan Cao, Suyu Wang, Mandar T. Naik, Yuan Fang, John Marshall, Chang-gong Lan, Cong Cao. Syn3, a newly developed cyclic peptide and BDNF signaling enhancer, ameliorates retinal ganglion cell degeneration in diabetic retinopathy. Protein Cell, 2024, 15(11): 858‒865 https://doi.org/10.1093/procel/pwae028

References

[1]
Cao C, Rioult-Pedotti MS, Migani P et al. Impairment of TrkB-PSD-95 signaling in Angelman syndrome. PLoS Biol 2013;11:e1001478.
CrossRef Google scholar
[2]
Castillo B, Jr., del Cerro M et al. Retinal ganglion cell survival is promoted by genetically modified astrocytes designed to secrete brain-derived neurotrophic factor (BDNF). Brain Res 1994;647:30–36.
CrossRef Google scholar
[3]
Fudalej E, Justyniarska M, Kasarello K et al. Neuroprotective factors of the retina and their role in promoting survival of retinal ganglion cells: a review. Ophthalmic Res 2021;64:345–355.
CrossRef Google scholar
[4]
Ji Y, Pang PT, Feng L et al. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci 2005;8:164–172.
CrossRef Google scholar
[5]
Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol 2008;586:4401–4408.
CrossRef Google scholar
[6]
Kimura A, Namekata K, Guo X et al. Neuroprotection, growth factors and BDNF-TrkB signalling in retinal degeneration. Int J Mol Sci 2016;17:1584.
CrossRef Google scholar
[7]
Lau KA, Yang X, Rioult-Pedotti MS et al. A PSD-95 peptidomimetic mitigates neurological deficits in a mouse model of Angelman syndrome. Prog Neurobiol 2023;230:102513.
CrossRef Google scholar
[8]
Marshall J, Zhou XZ, Chen G et al. Antidepression action of BDNF requires and is mimicked by Galphai1/3 expression in the hippocampus. Proc Natl Acad Sci U S A 2018;115:E3549–E3558.
CrossRef Google scholar
[9]
Naik MT, Naik N, Hu T et al. Structure-based design of peptidomimetic inhibitors of PSD-95 with improved affinity for the PDZ3 domain. FEBS Lett 2024;598:233–241.
CrossRef Google scholar
[10]
Sabanayagam C, Banu R, Chee ML et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol 2019;7:140–149.
CrossRef Google scholar
[11]
Seki M, Tanaka T, Nawa H et al. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004;53:2412–2419.
CrossRef Google scholar
[12]
Taslipinar Uzel AG, N UG, Toklu Y et al. Relationship between stages of diabetic retinopathy and levels of brain-derived neurotrophic factor in aqueous humor and serum. Retina 2020;40:121–125.
CrossRef Google scholar
[13]
Yanpallewar SU, Barrick CA, Buckley H et al. Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS One 2012;7:e39946.
CrossRef Google scholar

RIGHTS & PERMISSIONS

2024 The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.
AI Summary AI Mindmap
PDF(35060 KB)

Accesses

Citations

Detail

Sections
Recommended

/